| Updates on immunotherapy for colorectal cancer |
31 |
| Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition |
29 |
| The gut microbiome and colorectal cancer: a review of bacterial pathogenesis |
27 |
| Gastrointestinal stromal tumors: a comprehensive review |
20 |
| Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience |
17 |
| Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial |
15 |
| Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets |
11 |
| Outcomes associated with robotic approach to pancreatic resections |
11 |
| Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review |
11 |
| Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma |
10 |
| Immune profiling of microsatellite instability-high and polymerase epsilon (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy |
10 |
| Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma |
10 |
| A combined treatment of curcumin, piperine, and taurine alters the circulating levels of IL-10 and miR-21 in hepatocellular carcinoma patients: a pilot study |
9 |
| Hepatic metastasis from colorectal cancer |
9 |
| Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis |
9 |
| Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle |
9 |
| Age-related rates of colorectal cancer and the factors associated with overall survival |
9 |
| Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response |
9 |
| Immunotherapy in colorectal cancer: for the select few or all? |
9 |
| Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy |
8 |
| Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients |
8 |
| Management of locally advanced rectal cancer in the elderly: a critical review and algorithm |
8 |
| Does a stoma reduce the risk of anastomotic leak and need for re-operation following low anterior resection for rectal cancer: systematic review and meta-analysis of randomized controlled trials |
8 |
| Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies |
8 |
| Esophagectomy from then to now |
8 |
| Genomics and metagenomics of colorectal cancer |
8 |
| Making sense of adjuvant chemotherapy in colorectal cancer |
8 |
| Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study |
7 |
| Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy |
7 |
| Demographic disparities in delay of definitive chemoradiation for anal squamous cell carcinoma: a nationwide analysis |
7 |
| Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma |
7 |
| Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation |
7 |
| Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study |
6 |
| Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival |
6 |
| Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors-a single-institution experience |
6 |
| Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer |
6 |
| Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma |
6 |
| Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma |
6 |
| Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma |
5 |
| Overexpression of SSH1 in gastric adenocarcinoma and its correlation with clinicopathological features |
5 |
| Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma |
5 |
| Current survival and treatment trends for surgically resected intrahepatic cholangiocarcinoma in the United States |
5 |
| The accuracy of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as a marker for gastrointestinal malignancies |
5 |
| The platelets-neutrophils to lymphocytes ratio: a new prognostic marker in metastatic colorectal cancer |
5 |
| Prognostic value of multiple cytokine analysis in colorectal cancer: a systematic review |
5 |
| Identification of potential biomarkers and pathways in ulcerative colitis with combined public mRNA and miRNA expression microarray data analysis |
5 |
| Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma? |
5 |
| Large database utilization in health outcomes research in pancreatic cancer: an update |
5 |
| Exploring the differences between early-onsetgastric cancer and traditional-onset gastric cancer |
5 |
| Approach and management of checkpoint inhibitor-related immune hepatitis |
5 |
